SCROLL NEWS / DISCOVERY
Search headlines
Find the stories shaping the conversation.
Results for " pharma " 701 found 🔀 AI-powered Shuffle
Clearway Health Scales Operational Excellence with Appointment of Chief Operating Officer
/PRNewswire/ -- Clearway Health, a company that partners with hospitals and health systems to plan, build and operate specialty pharmacy programs, announces...
Aurora Appoints Seasoned Biopharmaceutical Executive to Lead Commercial Acceleration of Global Medical Cannabis Business
/PRNewswire/ -- Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces Faris El Refaie, a...
Springfield Health Department partners with Big Y for free vaccine clinics
The Springfield Department of Health and Human Services and Big Y Pharmacy have partnered this season to offer vaccine clinics for community members.
Scientists and algorithms: Finding the right balance in modern drug development
The future of drug development is not scientists versus algorithms. It is scientists and algorithms working together.
AZ's R&D chief Barr touts internal 'science success story' after IL-33 antibody's stellar showing in COPD
With a detailed data drop that AstraZeneca’s R&D chief described as an internal “science success story,” the British Big Pharma has secured an FDA priority review for what it believes could become a flagship biologic in chronic obstructive pulmonary disease (COPD). In detailed results from the late-stage Oberon and Titania trials—first teased in March and detailed in full at the European Respiratory Society Congress in Barcelona this week—the drugmaker laid out the extent of its IL-33 inhibitor’s potential to reduce moderate and severe exacerbations in a wide range of COPD patients still struggling with those “lung attacks,” as AstraZeneca’s Sharon Barr, Ph.D., called them, despite using standard-care inhaled therapy. In the headline results, a 300 mg dose of tozorakimab given once every four weeks curbed those moderate and severe exacerbations in the studies’ primary population of former smokers by 29% in the Oberon study and 34% in Titania. In the overall population of both current and former smokers, these reductions were 30% and 29%, respectively, versus placebo and inhaled standard of care. The benefits also extended to clinically meaningful exacerbation reductions in all prespecified patient subgroups and specifically turned up promising signals in patients across a range of blood eosinophil counts, with Barr telling Fierce that “it’s the details that make this even more exciting than the high-level results that we’ve already shared.” In fact, during AZ’s tozorakimab poster presentation at the ERS 2026 Congress this past weekend, attendees were so enamored by the data that event organizers had to encourage people to clear the room and look at the other presentations on offer, Barr said in an interview. “I think it really speaks to the fact that there is a lot of buzz around these data because the entire respiratory community has been so desperate for new therapies for these patients,” she explained. The respiratory disease continues to represent a “staggering unmet medical need,” Barr said, highlighting the COPD exacerbations that the Oberon and Titania studies homed in on, which she added carry a greater mortality risk than a heart attack. “When a patient has a severe exacerbation, only about half of them are still alive within three and a half years,” she pointed out. As for tozorakimab specifically, Barr christened the molecule “an AstraZeneca science success story,” harkening several years back to the point at which researchers began to explore IL-33 as a driver of respiratory disease, and COPD in particular. At the same time, “there was still so much that wasn’t understood,” she admitted, highlighting the insight that IL-33 signals through both ST2 and EGFR through the RAGE pathway, a discovery Barr attributed to AstraZeneca's own scientists. Understanding the need to tackle both pathways in COPD—and aware of competitor candidates in the hopper, including one that bound ST2—the company ultimately had to make some “courageous decisions,” Barr said. These included taking a prior COPD molecule offline and going back to the drawing board to reinvent its potential IL-33 label “to make sure that we had a molecule that could block signaling through both arms of the pathway, through both the reduced form and the oxidized form, knowing that we wouldn’t be first, but striving to be best.” “When we put [tozorakimab] into the clinic, we firmly believed that we had a differentiated molecule, and we saw the other molecules blocking just ST2 or partially blocking IL-33, unable to deliver two positive pivotal studies in COPD,” Barr explained. “We kept marching forward because we believed our molecule was differentiated, and now I think we have the clinical validation that supports that.” Ultimately, AstraZeneca finds itself on much better footing these days when it comes to potential biologic rivals to tozorakimab in COPD. Sanofi and Regeneron’s Dupixent, for instance, is approved to treat COPD exacerbations in patients with high eosinophil counts, but not low ones. Meanwhile, the future has become cloudier for other next-gen IL-33 candidates from Sanofi and Regeneron, as well as Roche, which have suffered trial flops in recent years. One other potential ingredient for AstraZeneca’s success in its duo of studies was that the company was “ambitious in the trial design, willing to look at an all-comers population,” Barr said, “and willing to enroll the most severe patients.” Prior studies for would-be biologics rivals in COPD “avoided enrolling” those patients, she pointed out. She also highlighted the Big Pharma’s painstaking design of exacerbations in its trial, which “gave us a very rigorous readout,” and pointed to “the extra effort and investment” the company put in to understand the effect of mucus plugs in patients. Barr described mucus production as a “key feature in disease diversity,” noting that mucus plugs—obstructing clumps of mucus that block patients’ airways—are associated with worse outcomes in COPD. In its data announcement, AstraZeneca noted that an integrated analysis of Oberon and Titania found tozorakimab “demonstrated a reduction in patients’ mucus plug score,” with the pharma claiming its biologic is the first to deliver such results in a broad COPD population. “So being able to reduce those mucus plugs, we expect, is an important part of driving benefit for patients who are living with COPD,” Barr said. Again touching on the breadth of the study populations, Barr added that tozorakimab “worked across all eosinophil levels in both current and former smokers across all levels of lung function,” which she suggested “really simplifies decision-making for clinicians, and it allows them to offer therapy to the broadest possible patient population.” In the highest patient eosinophil count group, tozorakimab helped chart a 43% reduction in exacerbation risk, which Barr stressed were “unprecedented data.” In the mid-level group, AZ’s drug delivered a 23% reduction and, in the lowest group, a 34% reduction in eosinophils, which Barr said suggests efficacy “in all patient subgroups.” As for AZ’s recent guidance upgrade on the medicine’s sales opportunity, the lift from a $3 billion to $5 billion range to $5 billion plus was informed by multiple factors, Barr said, including the fact that “in 2024, there were multiple competitors, and there aren’t anymore.” Additionally, “we know that this is a massive unmet medical need, and this is a really incredible set of data that we think will be very convincing to the clinical community,” Barr said. Looking ahead to a potential evolution of the COPD treatment landscape, Barr noted that most patients start treatment in the community with an option like a triple therapy, and for them, having an option like AstraZeneca’s inhaler Breztri will remain a “really important part” of that journey. But of the patients uncontrolled on triple therapy, which Barr described as “about half of them today,” just a “small fraction” are currently eligible for biologic therapy, which she emphasized AstraZeneca is working to change. Understanding that COPD is not a “one-size-fits-all” disease, AstraZeneca is also looking at its antibody drug Tezspire for patients with T2-driven disease, and the company continues to think about new mechanisms for tackling COPD through both systemic and inhaled drugs, Barr said.
SC's Emerging Biotech Industry Receives National Recognition
Genetic Engineering & Biotechnology News (GEN) recently named the Palmetto State among its “Regional and State Clusters to Watch” in its first-ever Next 10 U.S. Biopharma Clusters report, highlighting emerging life sciences ecosystems beyond...
Optimi Health to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
VANCOUVER, British Columbia, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Optimi Health Corp. (Nasdaq: OPTH) (CSE: OPTI) (“Optimi” or the “Company”), a commercial-stage pharmaceutical manufacturer of regulated psychedelic drug products, today announced that it will participate in the H.C. Wainwright 28th Annual Global Investment Conference. The conference will be held September 14-16, 2026, at the Lotte New York Palace Hotel. A Company presentation will be available on demand here beginning Friday, Septem
Bausch Health and YUN Announce Expansion to Mexico and Across Additional EMEA Markets
/PRNewswire/ -- Bausch Health Companies Inc. (NYSE: BHC)(TSX: BHC), a global, diversified pharmaceutical company, and YUN, a Belgian innovator in pioneering...
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
Osaka has the science. Now it needs the business
Osaka is striving to turn world-class life sciences research into a global healthcare industry - testing whether Japan's pharma and biotech sector can finally scale internationally.
The Market Forces Quietly Adding Thousands to Patient Bills
The true cost of “vertical integration”: patients directed to a higher-priced location for procedures. Or forced to buy from their insurer’s wholly owned pharmacy, which may not stock the drug prescribed or provide it at the lowest price.
Opinion | Pulling our health care system back from grip of catastrophe
Readers react to a recent essay, raising concerns about the influence of insurers and Big Pharma and questions about how to pay for Medicare for All.
GenSight Biologics Provides September 2026 Business Updates
PARIS, September 08, 2026--Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today provided business updates covering the summer of 2026 and confirmed the publication date for the Company’s financial statement covering the first half of 2026.
4 CDMOs to consider when outsourcing manufacturing
Contract development and manufacturing organizations looking to do business with biopharmas include Lonza, which has more than 30 sites, and Samsung Biologics, which recently announced a planned acquisition of another CDMO.
CVS Health (CVS) Makes Updated 2026 2027 COVID 19 Vaccines Available Nationwide
CVS Health (NYSE:CVS) announced that updated 2026-2027 COVID-19 vaccines are now available at CVS Pharmacy and MinuteClinic locations across the United States. The company is offering the new vaccines nationwide, with appointments and walk-in options across its retail and clinic network. CVS Health is integrating COVID-19 shots with other vaccinations, aiming to streamline access to multiple immunizations in a single visit. This kind of broad vaccine rollout highlights how large pharmacy...
Water damage at Nehalem Bay Health Center and Pharmacy fully repaired
The failure of a plumbing connection at the Nehalem Bay Health Center & Pharmacy (NBHCP) on May 12, 2026. resulted in considerable damage to flooring, dry wall and some equipment,
Jim Cramer Notes Cardinal Health (CAH) is “Too Attractive to Ignore”
On the September 2 episode of Mad Money, Jim Cramer called Cardinal Health, Inc. (NYSE:CAH) one of his “absolute favorites” and mentioned its growing exposure to specialty pharmaceuticals and higher-margin healthcare services. Cardinal’s been running circles around McKesson and Cencora. They consistently put up the best numbers because this company has gradually become less of […]
People on the Move: Leo Russo, PhD, Joins Life Science Cares Philadelphia Board of Advisors
Life Science Cares Philadelphia has welcomed Leo Russo, PhD, to its Board of Advisors, bringing more than 25 years of pharmaceutical industry experience in…
Cresco buys 9 Pennsylvania weed stores from PharmaCann
The deal will increase Cresco’s store count in Pennsylvania to 27 from 18, making it the largest cannabis retailer and wholesaler in the state.
Beyond Finger Pointing: The Fight to Lower Health Care Costs
In a live conversation recorded at Aspen Ideas: Health, executives from a hospital, insurer and pharmacy join a top Trump administration official and leading health economist to discuss how to collectively bring down health care costs.
Biopharma needs more data scientists. Who's getting hired?
With U.S. data science jobs projected to grow 35% over the next decade, a recruiter and talent strategy director discuss the qualifications, technical skills and mindset needed to land these coveted positions.
From Pandemic Prevention to Pharmaceutical Resilience: Why Health Security Should Be Part of US-Taiwan Economic Security Cooperation
As strategic competition in the Indo-Pacific region intensifies, Washington increasingly views Taiwan as both a reliable partner for democracy and regional stability, and as a critical contributor to supply-chain resilience and technology security. However, one important area has room for improvement: health security and pharmaceutical resilience.
This environment is antagonistic to local business
Last week, The News-Gazette reported on a real estate covenant gumming things up for a potential locally owned and operated pharmacy in Urbana. As you may recall, both the Walgreens and CVS on Philo Road ...
Women in Science: Dr Sabina Auhunas - TIB-Blog
The blog series “Women in Science” introduces women from the TIB who give insights into their careers and personal experiences in science. Dr Sabina Auhunas studied Pharmacy at Bogomolets National Medical University, and obtained her PhD in Pharmaceutical Sciences at Shupyk National Healthcare University of Ukraine in Kyiv and is now working at TIB (Open Science Lab). In this interview, she talks about diversity, shifting directions and persistence in academia.
CVS Health hires Dentsu Creative, retains Omnicom for media
Dentsu Creative will support the pharmacy and insurance giant’s creative efforts, while Omnicom retains media duties.
LOVB announces CVS Pharmacy as an Official Health & Wellness Partner
CVS Pharmacy and League One Volleyball (LOVB) launch a multi-year partnership featuring health programs, community engagement and a league-wide jersey patch sponsorship.
WATCH: Trump says more pharmaceutical companies will lower drug prices
A winner, a loser, and a mid-stage signal from a major cardiology research conference
The mental health system after Lindsay Clancy, pushing boundaries for new radiopharmaceuticals, and more health news from Morning Rounds
UToledo College of Pharmacy and Pharmaceutical Sciences Welcomes Largest Pharm.D. Class in 5 Years
White Coat Ceremony marks the start of the professional journey for 135 incoming pharmacy and pharmaceutical sciences students.
Federal Rescheduling Sets The Stage For Marijuana Business Acquisitions As Pharma And Ag Firms Eye Industry (Op-Ed)
“The practical question isn’t whether this is something to celebrate, it’s whether your business is positioned to be a consolidator, an attractive acquisition target or something different.” By Christopher B. Lynch, Dickinson Wright PLLC There are a lot of rumors and misinformation out there about what the April 23 federal marijuana rescheduling order means. Some […]
Boston Scientific hit by cyberattack causing ‘disruptions’ to parts of its business
This year has seen a growing number of medtechs hit by cyberattacks, and now Boston Scientific has become the latest victim. In an SEC filing posted Aug. 26, the medtech giant said it had detected a “cybersecurity incident” the day before. The incident has affected certain parts of its information technology systems, something that “has resulted in a global disruption to the company’s operations.” The incident has hit not just its information systems but also its business applications, which “support aspects of the Company’s operations,” it said in the filing. This includes its ability to process and ship customer orders. Boston Scientific said it is working to restore the systems, but the timeline remains unknown. Related Baylor Genetics hit by cybersecurity attack targeting patient, staff information As the company investigates the incident, it remains unclear how significantly its business will be affected. “Accordingly, the Company has not yet determined whether the incident is reasonably likely to have a material impact.” The company’s shares were down 3.5% in premarket trading as the news broke. This adds another layer of pressure for the medtech, which last month revealed a new global restructuring program that starts this year and is slated to be completed by 2029. The company said at the time that it “does expect some headcount reductions to result from these restructuring activities,” but did not provide any numbers or specify areas where the cuts may be made. It added, however, that new jobs are also set to be “created in areas of growth.” It was also forced to cut its sales guidance in Q2, saying in late July that it now expects full-year 2026 organic revenue growth of 5% to 6%, down from its previous guidance of 6.5% to 8%. Boston Scientific is one of a growing number of life sciences companies, notably medtechs, that have been hit by cyberattacks this year. These include Abbott, iRhythm, Medtronic and Stryker, as well as Big Pharmas Amgen and Novo Nordisk.
Thyroid medication recalled nationwide after tablets found to be 'superpotent': FDA
Vitruvias Therapeutics is recalling one lot of Thyroid Tablets, USP 30 mg, distributed nationwide after testing found the medication could be more potent than intended
Thyroid medication recalled nationwide due to possible ‘superpotency’ issue
A pharmaceutical company is recalling 3,655 thyroid tablets sold nationwide because they could be more potent than usual and may bring about health issues for people who use them.
ARCH and Population Health join China blitz with Haisco deal
Haisco Pharma partners with ARCH Venture's Bob Nelsen & Population Health Partners' Clive Meanwell to launch Sentivera in a $1.5B+ deal for ex-China rights to a type 2 inflammatory disease drug.
Pharmacy industry changes prompt closures of two longtime Yakima Valley businesses
Two pharmacies with longtime roots in the Yakima Valley will close in the next few weeks, part of a trend their owner attributes to third-party prescription management companies and more
Moving science out of silos: A conversation with biochemist and philanthropist Mick Hitchcock, Ph.D.
Biochemist Mick Hitchcock reflects on his career in pharmaceutical innovation and his commitment to advancing science and communication at the University of Nevada.
Chuck Stevens named president of RTI Health Solutions
RTI Health Solutions names Chuck Stevens as president, bringing more than 25 years of biopharmaceutical and life sciences leadership experience.
Mozambique strengthens regulation of medicines and imported vaccines, boosting health protection
Mozambique has reached a major milestone in strengthening the regulation of medicines and imported vaccines, with its national regulatory authority recognized by the World Health Organization (WHO) as having a stable, well-functioning and integrated regulatory system.The Autoridade Nacional Reguladora de Medicamentos de Moçambique (ANARME) has achieved Maturity Level 3 (ML3) for the regulation of medicines and imported vaccines under WHO’s global classification of national regulatory authorities.Mozambique becomes the 10th country in Africa to reach ML3, joining Egypt, Ethiopia, Ghana, Nigeria, Rwanda, Senegal, South Africa, Tanzania and Zimbabwe and marking further momentum in strengthening regulatory systems across the region.For people in Mozambique, stronger regulation means greater assurance that medicines and vaccines are appropriately evaluated for quality, safety and efficacy and monitored throughout their lifecycle. It also strengthens the country’s ability to identify and respond to safety concerns and substandard or falsified products, while supporting timely access to quality-assured health products.“Mozambique’s achievement is the result of sustained investment in regulatory capacity that will deliver crucial benefits for public health,” said Dr Sylvie Briand, WHO Chief Scientist and Assistant Director-General a.i. for Health Systems, Access and Data. “Strong regulatory systems protect people, build confidence in health products and help countries respond more effectively to evolving public health needs and challenges. Mozambique’s progress also contributes to advancing regulatory capacity across Africa and promoting more equitable access to safe and quality-assured medicines and vaccines.”Building a stronger regulatory systemMozambique’s achievement follows years of sustained efforts to build the institutions and capabilities needed for effective regulation.WHO worked closely with ANARME throughout this process, assessing the national regulatory system and supporting the authority in addressing identified gaps and strengthening priority areas.WHO evaluates national regulatory systems using its Global Benchmarking Tool (GBT), which assesses the regulatory functions required to ensure the quality, safety and efficacy of medical products. These include registration and marketing authorization, licensing, market surveillance and control, pharmacovigilance, regulatory inspection, laboratory testing and oversight of clinical trials, as applicable. WHO’s maturity levels range from 1 to 4. Reaching ML3 confirms a stable, well-functioning and integrated regulatory system, while ML4 represents an advanced system focused on continuous improvement.Benefits for Mozambique and the African continentAn ML3 regulatory system can support more timely and predictable regulatory decisions, reinforce safety monitoring and help ensure that health products entering and remaining on the market meet appropriate standards.It also creates greater opportunities for regulatory cooperation and reliance – approaches that help authorities make use of the work and decisions of trusted regulators, reduce unnecessary duplication and allocate limited resources more efficiently, while maintaining rigorous standards for quality, safety and efficacy.As the first Portuguese-speaking country in Africa to reach ML3, Mozambique’s experience can also contribute to strengthening regulatory systems and fostering greater cooperation, knowledge sharing and reliance among Portuguese-speaking countries and across the African continent. Its achievement further reinforces a more connected African regulatory ecosystem, providing a solid foundation on which the newly established African Medicines Agency can build to advance regulatory convergence and cooperation across the region.Strengthening confidence in regulatory recognitionMozambique’s achievement comes as WHO strengthens the process through which the performance of national regulatory systems is recognized.The newly established Technical Advisory Group on Regulatory Systems Strengthening (TAG-RSS) brings together independent international experts to advise WHO on whether recommendations concerning regulatory authorities reaching ML3 and ML4 and WHO-Listed Authorities, are supported by the findings of WHO evaluation processes. Its recommendations provide an additional level of independent assurance, strengthening the impartiality, transparency and credibility of WHO’s recognition process.Mozambique is among the first countries to achieve ML3 following consideration and recommendation by the TAG-RSS. As part of the same TAG-RSS process, South Africa was recommended to retain its ML3 status for the regulation of vaccines manufactured, imported or distributed in the country, following an additional WHO assessment. This extends the recognition first granted in 2022 and underscores the sustained performance of the South African Health Products Regulatory Authority (SAHPRA).The two recognitions highlight continued progress in strengthening regulatory systems across Africa, as well as the importance of continued performance, improvement and assessment in sustaining regulatory maturity.WHO will continue working with ANARME and SAHPRA to sustain these gains and support continuous improvement as science, technologies and public health needs evolve.
Edgewise Therapeutics Announces Upcoming Late-Breaking Science Presentation at the European Society of Cardiology (ESC) Congress 2026
/PRNewswire/ -- Edgewise Therapeutics, Inc. (Nasdaq: EWTX), a leading clinical-stage biopharmaceutical company focused on cardiovascular diseases, today...
Human creativity still has the edge – and this CEO says an MBA can help you use it
Emerging technologies are changing the face of Australian business, but this pharmaceuticals CEO says there’s still plenty of room for human creativity, if you’ve got the right tools
CVS Health Stock Is Beating the Market in 2026. Here's Why Wall Street Thinks It Can Soar Another 22%.
One of the pharmacy operator's segments is doing particularly well.
Watch: Mark Cuban Says You Can’t Fix Healthcare Until Every Price Is Known
With his online pharmacy, Mark Cuban changed how generic drugs are sold — and he has thoughts about how to fix the healthcare system. The billionaire businessman talks to KFF Health News’ Julie Rovner to answer the question: “How Would You Fix It?”
Opinion: The science that protects our children doesn't take a summer vacation
Connecticut's own biopharmaceutical community has played an important role in advancing vaccine science.
Costco plots major expansion into senior healthcare with Medicare partnership
In a first-of-its-kind venture, Costco is partnering with SCAN Health Plan on senior-focused insurance products that could include pharmacy, vision and hearing benefits.
A popular sleeping pill stuns scientists with unexpected Alzheimer’s breakthrough - Futura-Sciences
An Unlikely Ally Hidden in the Medicine Cabinet Alzheimer’s disease, the bane of an aging brain, might just have found itself an unexpected friend right in our own pharmacies. Researchers from Washington University in St. Louis have shed new light on the connection between sleep and brain health. They found...
Big Pharma trade group joins legal fight against Illinois drug discount law
PhRMA's lawsuit is the latest challenge to state-based laws designed to protect hospitals, clinics and pharmacies from unfettered access to 340B discounts.
Newsom Promotes Affordable Insulin, But California's Generic Label Off To A Slow Start
By Angela Hart and KFF Health News HealthDay ReportersTUESDAY, Aug. 18, 2026 (HealthDay News) — At a Walgreens in San Francisco’s bustling Japantown neighborhood, pharmacist Margaret On stocks two boxes of long-acting insulin pens from California’s new prescription drug label, CalRx, emblazoned ...
The New Love Center and River Valley Health partner for Food Pharmacy
The New Love Center and River Valley Health held a ribbon cutting ceremony to celebrate the launch of their Food Pharmacy, a partnership with the goal of delivering nutritious foods to clients using the facility. The project had been in the works for roughly six months when River Valley Health reached out to The New […]
Citius Oncology, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
/PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), an oncology-focused biopharmaceutical company and majority-owned...
Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
/PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a biopharmaceutical company dedicated to the development and...
Pace appoints Andy Fenny as president to drive life science growth
Pace, a science and technology company, has appointed Andrew (Andy) Fenny as president of Pace Life Sciences, the organization’s life sciences division, to lead the business into its next phase of strategic growth with a focus on expanding support and capacity for pharmaceutical and biotech clients across the development cycle.
See businesses that stay in Metcalfe Park and surrounding areas
Several businesses remain in Metcalfe Park despite corporate divestment, including locally owned Hayat Pharmacy, Bill the Butcher, and more.
Azitra, Inc. Announces Q2 2026 Results and Provides Business Updates
/PRNewswire/ -- Azitra, Inc. ("Azitra" or the "Company") (NYSE American: AZTR), a clinical stage biopharmaceutical company focused on developing innovative...
Eloxx Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Business Update
Completed underwritten public offering with gross proceeds of $66.0 million and uplisting to the Nasdaq Capital Market, significantly strengthening the...
Henry Ford Health to close St. Clair emergency room
Henry Ford Health to close River District Hospital ER Sept. 1; inpatient services end, labs/pharmacy remain open.
Campbell unites pharmaceutical science, clinical research in future-focused degree
The reimagined bachelor’s program prepares students for careers across the entire drug development lifecycle, with an emphasis on hands-on experience… More on this post
Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
First extracellular protein degraders in the clinic demonstrate rapid and robust pharmacodynamic effects and compelling safety in nearly 200 individuals dosed,...
Funding Science for the Long Term: The Role of Private Philanthropy
A drug that reaches a pharmacy shelf today often rests on discoveries made decades earlier. Yet the institutions financing scientific research do not
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year to $199.9 million. The company’s full-year revenue guidance of $840 million at the midpoint came in 3.4% below analysts’ estimates. Its non-GAAP profit of $1.92 per share was 8.8% above analysts’ consensus estimates.
Delaware expands health care access with new laws giving pharmacists, dental hygienists more responsibilities
A trip to the pharmacy could soon look different for Delaware patients. Governor Matt Meyer recently signed a package of healthcare legislation aimed at expanding access to care.
COLL Q2 Deep Dive: ADHD Expansion and Pain Business Headwinds Shape Guidance
Pharmaceutical company Collegium Pharmaceutical (NASDAQ:COLL) fell short of the market’s revenue expectations in Q2 CY2026, but sales rose 6.3% year on year ...
Did saving the pharmacy help Costco’s business center plan? What KC leaders say
The City Council made a final decision on Costco’s zoning request for its plans to convert the midtown store into a business center.
Wisconsin pharmacist says Trump’s tariffs could end his business
The owner of Fitchburg Family Pharmacy says his pharmacy could close due to Trump’s tariffs on generic drugs.
Sanofi suspends chronic lung disease phase 2 study, tied to ‘strategic business reasons’
Sanofi halted a phase 2 trial testing a monoclonal antibody, SAR445399, in non-cystic fibrosis bronchiectasis, Fierce Biotech has learned. The trial, which began only back in April, was a randomized, double-blind, placebo-controlled study to measure the reduction in mucus plug score following treatment with SAR445399 compared with placebo in adults aged 18 to 80 years with NCFB, a chronic lung disease. The trial was officially reported as halted on July 29, the day before Sanofi’s second-quarter earnings call. The decision to pause the trial was made “as part of a company-wide portfolio review for strategic business reasons,” and not due to safety concerns, a Sanofi spokesperson told Fierce. The move to pause the NCFB trial comes during a trying time for Sanofi following a year filled with a series of trial fails. In February, the French pharma ousted CEO Paul Hudson and appointed Merck KGaA leader Belén Garijo, M.D., Ph.D., to steer the ship. Since then, Garijo has been doing a deep dive on correcting the company’s strewn R&D and clinical strategies. On July 24, Sanofi scrapped amlitelimab for atopic dermatitis, despite its lore as being a potential $5 billion blockbuster. During its second-quarter report, the company abandoned two more assets, balinatunfib and itepekimab, following failed trial results in psoriasis and chronic obstructive pulmonary disease, respectively. SAR445399, only first revealed by Sanofi in 2023, is an anti-interleukin-1 receptor 3 monoclonal antibody developed to block the interleukin 1, 33, and 36 cytokine pathways. These pathways can be important in chronic immune-related dermatologic diseases, such as atopic dermatitis and hidradenitis suppurativa, as well as respiratory conditions, such as NCFB. Related Sanofi’s new CEO ‘looking deeply’ at late-stage pipeline as clinical clearout continues NCFB affects roughly half a million people in the U.S., with a global incidence of greater than one million cases. In August 2025, Insmed received FDA approval for Brinsupri, a DPP1 inhibitor targeting neutrophil activation, for treatment of NCFB in adults and kids ages 12 and older. The British biotech Infex Therapeutics showed promising NCFB phase 2a data using their monoclonal antibody, INFEX702, which acts by disabling Pseudomonas aeruginosa, a bacteria known to be a major pathogen of NCFB. Sanofi is currently running a separate phase 2 study testing SAR445399 as a potential treatment for the inflammatory skin condition hidradenitis suppurativa.
AI generates personalized radiopharmaceutical therapy doses in under 23 seconds
The model has the potential to improve upon the one-size-fits-all dosing approach used for most RPT prostate cancer treatments.
Councilman says Midtown Costco will continue to provide pharmacy services in transition to business center
Costco leadership has reportedly agreed to continue to provide pharmacy services at the Midtown location if and when it transitions to a business center.
Ocular Therapeutix Reports Second Quarter Revenue, Provides Business Highlights
BEDFORD, Mass.—Ocular Therapeutix, Inc. (NASDAQ: OCUL), an integrated biopharmaceutical company in the retina space, has reported financial results for the second quarter ended June 30, 2026, and provided recent business highlights. Total net revenue was $13.5 million for the second quarter of 2026, flat as compared with the same period in 2025. The company also reported a net loss of $78.8 million for the quarter, compared with a net loss of $67.8 million for the comparable quarter of 2025.
BrightSpring earnings skyrocket in Q2 on strength of pharmacy, home health
Driven by continued growth in its specialty pharmacy and recent acquisitions in its home health business, BrightSpring Health Services reported strong revenue and earnings in the second quarter of 2026.
Big deals: Pharma, manufacturing make splash in Virginia
Anticipated to create at least 100 jobs apiece, these economic development announcements were some of the largest in Virginia in the second half of 2025
UMB Celebrates America at 250: Addition of Pharmacists Gives the Health Care Field a Shot in the Arm
Founded in 1841, the School of Pharmacy helped turn a trade into a profession, shaped pharmacy education and practice in Maryland, and has extended its impact to the nation and the world.
Senate Panel To Examine Biotech's Role in U.S. Health Resilience
Senate Finance Committee investigates biotech's impact on U.S. health resilience as China gains pharmaceutical advantage. Hear expert testimony August 4.
How a CT couple keeps a rare business going after 40 years. And yes, vacations are rare.
“If you don’t put everything into it, you’re not going to have people coming in,” the owner said.
Cybersecurity and business among new academic programs at Gwinnett schools
When the 2026-2027 school year begins on Wednesday, some Gwinnett County Public Schools students will begin their educations in fields such ranging from cyber security, pharmacy operations and patient care
N.C. health experts warn about Medicare Part D changes
Medicare literacy experts encourage participants to seek help or educate themselves on the changes that will be implemented in 2027.
FDA advisers support easing restrictions on six peptides. Here’s what those drugs are and what happens next
Peptides have become one of the hottest trends in wellness, with promises like faster muscle recovery and healthier aging. And six of these compounds cleared a major hurdle last week, when an advisory panel to the US Food and Drug Administration voted in favor of making them available through compounding pharmacies.
Cigna raises annual profit forecast on strength in health services unit
Cigna on Thursday raised its annual profit forecast, after beating quarterly earnings estimates on growth in its pharmacy and specialty drug businesses.
Cigna Reports Earnings Thursday With New CEO, New Business Model
Cigna Group will report its earnings on Thursday under its new chief executive, Brian Evanko. It’s transitioning its pharmacy benefits business to a rebate-free model.
UConn School of Pharmacy and Pharmaceutical Sciences Professor Xiuling Lu Receives Director Promotion
UConn School of Pharmacy and Pharmaceutical Sciences Professor (SoPPS), Xiuling Lu, was recently announced as the new Director of Research and Graduate Educ ...
Why benchmarking clinical LLMs from OpenEvidence, Doximity is complicated
In this edition of AI Prognosis: A conversation about benchmarking leading clinical chatbots, investor view on AI in biopharma, and more.
Costco midtown store nears business center switch amid concerns, may keep pharmacy
Councilman Crispin Rea said keeping the pharmacy would be “a big win” for the neighborhood’s most vulnerable residents.
Big Pharma gets a lesson in trusting the science
J&J reached a relatively cheap $5.5 bln settlement that could end over a decade of litigation related to talc. The healthcare giant exited Kenvue, its former consumer goods unit, partly to escape similar legal worries. In retrospect, it looks to have handed a rival a deal.
Twisted laser light can tell mirror-image molecules apart
Scientists have created twisted laser beams that interact differently with right-handed and left-handed molecules, revealing their identity through the fragments they produce. The approach could provide a faster, simpler, and more sensitive way to analyze important molecules used in chemistry and pharmaceuticals.
New pharmacy opens in Pearland
Royal Atoms Pharmacy is now open in Pearland, staff said.
Pharma’s drug spending deflection
Job lock, surging prescription drug costs, No Surprises Act update, and more from STAT's Health Care Inc.
FDA rejects application for new oral MR imaging contrast agent
Biotechnology firm Ascelia Pharma is working to roll out Orviglance, a novel manganese-based product for visualizing focal liver lesions during MRI, but faced a recent setback.
Biotech is ‘leading innovative science, not universities’
Sharper mission and team ethos of pharma companies make them more effective than university labs, says Nobelist Fred Ramsdell
Tri-state people in business: New hires, promotions, recognitions
MedOne Pharmacy Solutions, of Dubuque, announced the following new hires:
High drug prices anger the public. Steep hospital costs elicit yawns. Why is that?
How is it that pharma companies—and, by extension, health insurers that cover drugs—have targets on their backs while hospitals live like wallflowers?
Medications Already in Pharmacies May Slow Aging, And Scientists Are Narrowing Them Down
But which ones?
Four pharmacy trends every business leader should be watching
Commentary: For business leaders trying to manage healthcare costs, the pharmacy component has become a strategic priority.
Albertsons warns of softer grocery demand as consumers pull back
Albertsons cut its annual outlook after comparable grocery sales declined, while digital and pharmacy growth helped offset pressure in its core business.
Industry and D.C. Are Racing Ahead on Psychedelics. They Should Let Science Lead.
President Trump and pharmaceutical companies are betting big on psychedelics. But hype isn't the same as scientific proof, and urgency must be coupled with caution.
Peptide boom has states scrambling to protect consumers, Post investigation finds
The Post surveyed states’ pharmacy, medical and nursing boards to reveal the gaping regulatory holes for medspas and peptides.
Erlanger Health System signs letter of intent to join Prisma Health
Erlanger Health System plans to join Prisma Health, creating a 27-hospital system in exchange for a $2 billion strategic capital commitment toward care in the Chattanooga, Tennessee area. | The tentative deal includes a $2 billion strategic capital commitment from Prisma, and would yield a 27-hospital, $9 billion operating revenue nonprofit in the southeast.
UT Pharmacy Again Enters NCPA Business Competition Finals
A team from The University of Texas at Austin College of Pharmacy is once again a finalist in NCPA's 2026 Good Neighbor Pharmacy NCPA Pruitt-Schutte Student Business Plan Competition. Texas Pharmacy's team will present its business plan during a live competition at October's NCPA Annual Convention in Kansas City.
Samsung Biologics: geographic diversification is a sound business decision
Samsung Biologics has been on a steep upward growth trajectory since receiving its first licence to produce biologic drug substances in 2015.
CVS is now filling pet prescriptions at its 9,000 pharmacies nationwide
The pharmacy chain will dispense select medications for dogs and cats, including antibiotics, insulin, and flea and tick treatments
Cardinal Health to buy Strive Medical, AdaptHealth's diabetes health business for $360M
Cardinal Health is pursuing two tuck-in acquisitions to expand its home care business. | The pharmaceuticals and specialty products distributor plans to buy AdaptHealth's diabetes health business unit and medical supply provider Strive Medical in separate deals worth $360 million.